Sarepta Therapeutics Stock News

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pr

Approval of Apellis' (APLS) Empaveli for treating paroxysmal nocturnal hemoglobinuria lends a significant boost to the company's growth prospects. The drug's label expansion studies also hold promise.

Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.

CAMBRIDGE, Mass., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2021 t

Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well

Kodiak Sciences (KOD) progresses well with the development of its lead candidate, KSI-301, for treating various retinal vascular diseases. Stiff competition in the target market remains a woe.

Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.

Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.

Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

Banque Cantonale Vaudoise trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 59.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,569 shares of the biotechnology companys stock after selling 2,262 shares during the quarter. Banque Cantonale Vaudoises holdings in Sarepta Therapeutics were []

The Zacks Analyst Blog Highlights: Daqo New Energy, Pinterest, Sarepta Therapeutics, JOYY and Chindata Group

Eli Lilly's (LLY) pivotal phase III study on lebrikizumab in combination with topical corticosteroids meets the primary and key secondary endpoints.

Novartis (NVS) is set to acquire ocular gene therapy company Gyroscope Therapeutic. Generic arm Sandoz submits a marketing authorization application for a proposed biosimilar of Herceptin.